Sonoma Pharmaceuticals, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the adjourned annual meeting of stockholders held on November 5, 2019. The company is incorporated in Delaware and its common stock (SNOA) and warrants (SNOAW) trade on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
At the meeting, 677,052 shares were present or represented by proxy out of 1,329,726 shares entitled to vote. Stockholders approved the following proposals:
- Proposal 1 (Election of Director): Dr. Jay Birnbaum was elected as Class II Director with 386,614 votes for and 96,543 votes withheld.
- Proposal 2 (Executive Compensation): The advisory vote to approve executive compensation passed with 387,222 votes for, 63,644 against, and 32,291 abstentions.
- Proposal 3 (Auditor Ratification): The appointment of Marcum LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2020, was ratified with 589,738 votes for, 35,220 against, and 52,094 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Dr. Jay Birnbaum has been elected to the Board of Directors.
- Marcum LLP is the confirmed independent auditor for the fiscal year ending March 31, 2020.
- Amy Trombly signed the report in her capacity as Interim Chief Executive Officer.
- Approximately 51% of the total outstanding shares were represented at the annual meeting.